Safety and efficacy of sorafenib followed by regorafenib or lenvatinib in patients with hepatocellular carcinoma
Hepatology Research2020Vol. 51(2), pp. 190–200
Citations Over TimeTop 23% of 2020 papers
Takeshi Terashima, Tatsuya Yamashita, Tatsuya Yamashita, Noboru Takata, Yasuhito Takeda, Hidenori Kido, Noriho Iida, Masaaki Kitahara, Tetsuro Shimakami, Hajime Takatori, Kuniaki Arai, Kazunori Kawaguchi, Kazuya Kitamura, Taro Yamashita, Taro Yamashita, Yoshio Sakai, Eishiro Mizukoshi, Masao Honda, Shuichi Kaneko
Abstract
Similar adverse events were experienced by patients during consecutive treatment with sorafenib and regorafenib, which was not observed during treatment with sorafenib and lenvatinib. The obtained safety profile of sorafenib provided meaningful insights for selecting sequential therapy for patients with advanced HCC.
Related Papers
- → Hepatocellular carcinoma(2018)5,512 cited
- → Tyrosine Kinase Inhibitors in the Treatment of Hepatocellular Carcinoma(2019)16 cited
- → Gelatin sponge microparticles for transarterial chemoembolization combined with regorafenib in hepatocellular carcinoma: a single-center retrospective study(2022)5 cited
- → New therapy including combination(2018)1 cited
- → Regorafenib combined with transarterial chemoembolization for unresectable hepatocellular carcinoma: a real world study(2021)5 cited